Baxter International | BAX - Cash And Equivalent



Baxter International reported $2.29B in Cash and Equivalent for its fiscal quarter ending in March of 2025.


Cash And Equivalent Change Date
Abbott USD 6.95B 419M Jun/2025
AtriCure USD 117.8M 17.91M Jun/2025
Avanos Medical USD 90.3M 6.7M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Becton, Dickinson and Co. USD 735M 68M Jun/2025
Boston Scientific USD 725M 311M Mar/2025
Cooper Companies USD 124.9M 8.7M Jul/2025
Dexcom USD 1.16B 254.1M Jun/2025
Edwards Lifesciences USD 3.14B 95.4M Mar/2025
Fresenius EUR 1.23B 1.16B Jun/2025
Globus Medical USD 229.45M 231.82M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
ICU Medical USD 300.02M 10.32M Jun/2025
Insulet USD 1.12B 107M Jun/2025
Integra LifeSciences USD 217.91M 21.19M Jun/2025
Intuitive Surgical USD 9.53B 431.3M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Laboratory Of America USD 647.3M 277.9M Jun/2025
Masimo USD 149.6M 18.8M Jun/2025
Medtronic USD 2.22B 978M Apr/2025
Merit Medical Systems USD 341.82M 53.71M Jun/2025
Quest Diagnostics USD 319M 131M Jun/2025
Stryker USD 2.38B 55M Jun/2025
Tandem Diabetes Care USD 64.11M 10.54M Jun/2025
Teleflex USD 253.7M 30.42M Jun/2025
Terumo JPY 204.29B 17.58B Jun/2025
Zimmer Biomet Holdings USD 556.9M 827.6M Jun/2025